Noel Tata seeks record of Tata Sons September 17 board meet

New Delhi, Oct. 26 -- Tata Trusts Chairman Noel Tata has sought the record of the Tata Sons board meeting on September 17, which approved N Chandrasekaran as Chairman for a third term, and has also qu... Read More

All Ability National Divyang Cricket Tournament 2026 announced

New Delhi, Oct. 26 -- All Ability National Divyang Cricket Tournament 2026 announced Mumbai (Maharashtra) [India], October 26: In a significant initiative to promote inclusive sports a... Read More

Railtel fixes record date for interim dividend

Mumbai, Oct. 26 -- Railtel Corporation of India has fixed 30 October 2026 as record date for the purpose of payment of interim dividend of FY 2026-27. The date of payment of dividend will be 20 Novemb... Read More

Verizon Lifts FY26 Outlook After Higher Q3; Signs $2 Bln AI Deal With AWS; Stock Drops

India, Oct. 26 -- Telecom major Verizon Communications Inc. on Monday reported higher third-quarter results and raised fiscal 2026 forecast. Further, the company announced that it has signed an agree... Read More

Nesco Q2 PAT declines 12% YoY to Rs 105 crore

Mumbai, Oct. 26 -- Revenue from operations declined 4.49% YoY to Rs 228.45 crore in Q2 FY27 from Rs 239.18 crore in the corresponding quarter last year. Profit before tax (PBT) stood at Rs 135.81 cro... Read More

Wazirin Tinubu: The influence and burden of Ibrahim Masari, By Umar Farouk Bala

Nigeria, Oct. 26 -- When the Tinubu Movement for Sustainable Governance Foundation, widely known as Tinubu Must Stay (TMS), inaugurated its national leadership in Abuja, I accepted the responsibility ... Read More

Singapore Clinical Trial: IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy.

Singapore, Oct. 26 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507... Read More

Singapore Clinical Trial: ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Singapore, Oct. 26 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemothera... Read More

Singapore Clinical Trial: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)

Singapore, Oct. 26 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safet... Read More

Singapore Clinical Trial: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy Versus Physician’s Choice of Chemotherapy in Participants With B7-H4-selected Advanced/Metastatic Endometrial Cancer Who Progressed on or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (BLUESTAR-Endometrial01)

Singapore, Oct. 26 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) M... Read More

• ««
• «
• 3605
• 3606
• 3607
• 3608
• 3609
• 3610
• 3611
• 3612
• 3613
• 3614
• »
• »»